Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease

Acta Neurologica Scandinavica, Supplement

Volumn 102, Issue 176, 2000, Pages 60-67

  Lahiri, D K ^a   Farlow, M R ^a   Hintz, N ^a   Utsuki, T ^b   Greig, N H ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Alzheimer's disease; Anticholinesterase; Beta amyloid precursor protein; Beta peptide; Butyrylch olinesterase; Cholinergic; Cholinomimetics; Neuroblastoma cells

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMYLOID PRECURSOR PROTEIN; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; METRIFONATE; PHENSERINE; PHYSOSTIGMINE; PROTEINASE; TACRINE; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CELL CULTURE; CEREBROSPINAL FLUID ANALYSIS; CHOLINERGIC NERVE; COGNITION; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MEMORY; NEOCORTEX; NEUROBLASTOMA CELL; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; IMMUNOHISTOCHEMISTRY; METABOLISM; NEUROBLASTOMA; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; CHOLINESTERASE INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; TUMOR CELLS, CULTURED;

EID: 0034489269     PISSN: 00651427     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Alzheimer's disease: Genotypes, phenotypes, and treatments
2. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
3. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
4. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia
5. The cholinergic hypothesis of geriatric memory dysfunction
6. The origins of Alzheimer disease: A is for amylold
7. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline
8. Processing of the β-amyloid precursor protein and its regulation in Alzheimer's disease
9. Alzheimer's disease: Pinning down phosphorylated tau
10. Cholinesterase inhibitors as therapy in Alzheimer's disease: Benefit to risk considerations in clinical application
11. Pharmacologic approaches to cognitive deficits in Alzheimer's disease
12. Translating cell biology into therapeutic advances in Alzheimer's disease
13. Purification and cloning of amyloid precursor protein beta-secretase from human brain
14. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
15. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity
16. Alzheimer's disease. The tangled tale of tau
17. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors
18. Calcium regulates processing of the Alzheimer's amyloid protein precursor in a protein kinase C-independent manner
19. Cholinesterase inhibitors do more than inhibit cholinesterase
20. Amyloid precursor protein fragment and acetylcholinesterase increase with cell confluence and differentiation in a neuronal cell line
21. The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells
22. Tacrine alters the processing of beta-amyloid precursor protein in different cell lines
23. Phenserine and ring-C hetero-analogues: Drug candidates for the treatment of Alzheimer's disease
24. An increased percentage of long amyloid-beta protein secreted by familial amyloid-beta protein-precursor (beta-APP (717)) mutants
25. The function of heat-shock proteins in stress tolerance: Degradation and reactivation of damaged proteins
26. New therapeutic approaches to cognitive impairment
27. 3H]5-hydroxytryptamine in rat hippocampal slices
28. Metrifonate: Update on a new antidementia agent
29. Oral physostigmine treatment of patients with Alzheimer's disease
30. A controlled trial of tacrine in Alzheimer's disease
31. Phenserine, a novel anticholinesterase related to physostigmine: Total synthesis, and biological properties
32. Systematic regional differences in the cholinergic inervation of the primate cerebral cortex; distribution of enzyme activities and some behavioral implications
33. Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines
34. A new and rapid colorimetric determination of acetylcholinesterase activity
35. Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions
36. Novel selective butyrylcholinesterase (BchE) inhibitors for the treatment of Alzheimer's disease
37. Clinical pharmacology of tetrahydroaminoacridine: A possible therapeutic agent for Alzheimer's disease
38. The effect of tacrine and leupeptin on the secretion of the beta-amyloid precursor protein in HeLa cells
39. Cholinesterase inhibitors: From the Calabar bean to Alzheimer therapy
40. The experimental Alzheimer drug phenserine: Preclinical pharmacokinetics and pharmacodynamics